comparemela.com

Latest Breaking News On - Nasdaq cnta - Page 1 : comparemela.com

Centessa Pharmaceuticals plc (NASDAQ:CNTA) Receives Average Rating of "Moderate Buy" from Analysts

Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) have been assigned an average rating of “Moderate Buy” from the seven research firms that are currently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company. […]

China
Karenm-anderson
Nasdaq
China-universal-asset-management-co
Centessa-pharmaceuticals-company-profile
Analyst-recommendations-for-centessa-pharmaceuticals
Centessa-pharmaceuticals-trading
Platinum-investment-management-ltd
Centessa-pharmaceuticals
Institutional-trading-of-centessa-pharmaceuticals
Franklin-resources-inc

Centessa Pharmaceuticals Announces $100 Million Proposed

BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) Centessa Pharmaceuticals plcĀ (Nasdaq: CNTA), a clinical-stage pharmaceutical company that.

London
City-of
United-kingdom
Boston
Massachusetts
United-states
New-york
Kristenk-sheppard
Exchange-commission
Leerink-partners
Prospectus-department

Head to Head Contrast: Centessa Pharmaceuticals (NASDAQ:CNTA) & Larimar Therapeutics (NASDAQ:LRMR)

Centessa Pharmaceuticals (NASDAQ:CNTA – Get Free Report) and Larimar Therapeutics (NASDAQ:LRMR – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership. Insider and Institutional Ownership 82.0% of Centessa […]

Altrincham
Trafford
United-kingdom
Pennsylvania
United-states
Bala-cynwyd
Centessa-pharmaceuticals
News-ratings-for-centessa-pharmaceuticals-daily
Larimar-therapeutics-inc
Get-free-report
Larimar-therapeutics

Centessa Pharmaceuticals (NASDAQ:CNTA) Given Outperform Rating at BMO Capital Markets

BMO Capital Markets reissued their outperform rating on shares of Centessa Pharmaceuticals (NASDAQ:CNTA – Free Report) in a research report report published on Monday morning, Benzinga reports. BMO Capital Markets currently has a $15.00 price objective on the stock. Centessa Pharmaceuticals Stock Performance Shares of CNTA stock opened at $10.37 on Monday. The business has […]

China
Karenm-anderson
Harris-rotman
Susquehanna-international-group
Hedge-funds-weigh-in-on-centessa-pharmaceuticals
Analyst-recommendations-for-centessa-pharmaceuticals
Centessa-pharmaceuticals-stock-performance
Centessa-pharmaceuticals-company-profile
News-ratings-for-centessa-pharmaceuticals-daily
China-universal-asset-management-co
Barclays-plc
Centessa-pharmaceuticals

Centessa Pharmaceuticals (NASDAQ:CNTA) Shares Down 5.6%

Centessa Pharmaceuticals plc (NASDAQ:CNTA – Get Free Report) dropped 5.6% during trading on Monday . The company traded as low as $11.48 and last traded at $11.52. Approximately 351,020 shares were traded during trading, a decline of 16% from the average daily volume of 419,941 shares. The stock had previously closed at $12.20. Centessa Pharmaceuticals […]

China
Harris-rotman
China-universal-asset-management-co
Nasdaq
Centessa-pharmaceuticals-stock-down
Barclays-plc
News-ratings-for-centessa-pharmaceuticals-daily
Securities-exchange-commission
Susquehanna-international-group
Prelude-capital-management
Centessa-pharmaceuticals
Hedge-funds-weigh-in-on-centessa-pharmaceuticals

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.